Who we are

World leaders in liquid biopsy, dedicated to advancing cancer care


We are committed to providing the best sample for a complete picture of a patient’s cancer


To make precision medicine a reality by advancing rare cell diagnostics

Our Parsortix technology has the potential to deliver profound improvements in clinical and health economic outcomes in the diagnosis and treatment of cancer

The patented Parsortix PC1 system is the first FDA cleared medical device for the capture and harvest of intact CTCs from metastatic breast cancer (MBC) patient blood for subsequent, user-validated analysis

The ability to monitor and analyze CTCs may transform the treatment of MBC, providing patients with personalized cancer care through a non-invasive, repeatable liquid biopsy

Product intended use

Discover more
An illustration of purple and green cancer cells

Our clinical laboratories utilize Parsortix technology in combination with both standardized and custom assays for the analysis of epithelial and mesenchymal CTCs for biopharmaceutical and translational researchers

These assays have the potential to provide clinicians with up-to-date, clinically actionable insight into a patient’s cancer, and may result in improved clinical outcomes for those individuals

Andrew Newland - Chief Executive ANGLE plc

A message from Andrew Newland

Discover how ANGLE can help with your liquid biopsy needs

Contact us

Parsortix PC1 system

Product Intended use: The Parsortix PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.


  1. Dive C, Brady G. SnapShot: circulating tumor cells. Cell. 2017 Feb 9;168(4):742-.
  2. Castro-Giner F, Aceto N. Tracking cancer progression: From circulating tumor cells to metastasis. Genome Medicine. 2020 Dec;12(1):1-2.